v3.25.3
Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating expenses [1] € (2,476) € (1,977) [2]
Other operating income [1] 533 563 [2]
Other operating income/(expenses), net related to Regeneron (2,261) (1,745)
Monoclonal Antibodies Alliance    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating expenses (2,327) (1,837)
Monoclonal Antibodies Alliance | Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating expenses (2,475) (1,934)
Monoclonal Antibodies Alliance | Additional share of profit paid by Regeneron towards development costs    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating income 494 389
Monoclonal Antibodies Alliance | Reimbursement to Regeneron of selling expenses incurred    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating expenses (346) (292)
Other (mainly Zaltrap and Libtayo)    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating income and expenses 66 92
Regeneron | Other operating income (expense)    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating income € 70 € 96
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.